Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective

Abstract

AIM: To assess the cost-effectiveness of interleukin (IL)-17A inhibitor secukinumab vs the currently licensed biologic therapies in ankylosing spondylitis (AS) patients from a Canadian healthcare system perspective. METHODS: A decision analytic model (semi-Markov) evaluated the cost-effectiveness of secukinumab 150 mg compared to certolizumab pegol, adalimumab, golimumab, etanercept and etanercept biosimilar, and infliximab and infliximab …

Authors

Goeree R; Chiva-Razavi S; Gunda P; Jain M; Jugl SM

Journal

Journal of Medical Economics, Vol. 22, No. 1, pp. 45–52

Publisher

Taylor & Francis

Publication Date

January 2, 2019

DOI

10.1080/13696998.2018.1539400

ISSN

1369-6998

Associated Experts

Ron Goeree

Professor Emeritus, Faculty of Health Sciences

Visit profile

Labels